Crystagen

Compound Overview

Research Use Only. Not for Human Consumption.

Crystagen is supplied by Nexus as a sequence-defined short peptide bioregulator for controlled in-vitro research and analytical workflows. The provided chemistry record identifies Crystagen as Glu-Asp-Pro, abbreviated EDP, a 3-residue synthetic peptide associated with thymic and immune-cell research models.

Crystagen is categorized in the Nexus catalog under Russian Bioregulators. The current Nexus variant is a 20mg research-size catalog item under SKU CRY20. The available source record supports its peptide sequence, classification, molecular formula, calculated molecular weight, physical form, intended use, and storage guidance. It does not provide a confirmed CAS number, lot-specific purity value, salt or counter-ion assignment, batch number, or Certificate of Analysis values.

Because the supplied source data is limited, this page is intentionally limited as well. It does not infer therapeutic properties, dosing information, biological outcomes, mechanism-specific findings, reconstitution instructions, or compound-specific stability windows beyond the facts included in the research record.

• Product: Crystagen
• SKU: CRY20
• Available Research Size: 20mg
• Class: Khavinson short peptide bioregulator
• Sequence: EDP
• Sequence Display: Glu-Asp-Pro
• Physical Form: Lyophilized powder
• Use: For in-vitro research use only. Not for human consumption.

Research Background & Published Literature

The available literature for Crystagen is concentrated in Russian and Eastern European bioregulator research. For this product record, the strongest usable chemistry anchor is the defined amino-acid sequence: Glu-Asp-Pro. That sequence provides the basis for the calculated molecular formula and molecular weight listed in the technical specifications below.

Crystagen is identified in the supplied research data as a Khavinson short peptide bioregulator associated with thymic and immune-cell research models. The provided record does not include detailed experimental abstracts, assay protocols, validated mechanism-specific findings, study conditions, or lot-level release analytics. For that reason, this page avoids unsupported statements about biological effects and treats the EDP sequence, classification, physical form, and computed chemistry values as the primary verified descriptors.

Storage, Handling & Stability Guidelines

Store lyophilized Crystagen material at -20°C, desiccated, and protected from light. These are the only Crystagen-specific storage parameters included in the current research record.

Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.

Laboratories should document handling conditions according to their own validated internal procedures and preserve traceability between aliquots, source material, and lot-level verification records. The absence of a provided stability study means this description should be treated as a conservative storage summary rather than a complete stability protocol.

Quality Assurance & Lab Verification

The Certificate of Analysis for this catalog item is pending. No provisional batch, assay, method, analyst, or release data is published in this product dossier. Check the Lab Verified archive for documentation status.